BIOB News and Press, Bio-Rad Laboratories Inc. Cl B From 10/27/22

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent c...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the third quarter of 2022 on Thursday, October 27, 2022, following the close of the market. Management will discuss these res...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE New...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent comp...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2022 on Thursday, July 28, 2022, following the close of the market. The company will discuss these resu...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its inaugural corporate sustainability report. The report is based on an assessment Bio-Rad conducted in 2021 to identify the highest priority t...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2022. First-quarter 2022 net sales were $700.1 million, a decrease of 3.7 percent compa...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2022 on Thursday, April 28, 2022, following the close of the market. The company will discuss these results in ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its underwritten public offering of $1.2 billion aggregate principal amount of the following notes (the “Notes”), each...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST today in New York City. During the event, members of Bio-Rad’s executive leadership team wi...